SubsidieMeestersThe scale-up of the BioMilk platform: The revolutionary approach to manufacturing of biopharmaceuticals
Bio-Sourcing aims to revolutionize biosimilar production with its BioMilk platform, leveraging CRISPR-engineered goats for cost-effective, sustainable manufacturing and securing licensing deals by 2027.
Projectdetails
Introduction
Bio-Sourcing has developed a BioMilk platform, a new paradigm-shifting technology to produce biosimilar molecules in the milk of genetically engineered goats. This breakthrough development produces genetically modified goats using CRISPR-Cas9, resulting in 100% pure progeny of goats with genes of interest for biosimilars.
Cost Efficiency
Our bioproduction method is:
- Up to 5x more cost-efficient, reducing costs from €100-200 to €25 per gram of API.
- 10x less CAPEX, reducing investment costs from €200-300 million to €35 million.
- 1000x lower CO2 footprint, reducing it from 25T to 5 per Kg of API, compared to conventional methods.
This allows for scalability and industrialization with significantly less carbon footprint.
Market Potential
The BioMilk platform has the potential to be market-creating and disrupt the biotherapeutics manufacturing and biosimilar markets, with an enormous market opportunity of €100B.
Project Goals
The main goal of the project is to:
- Successfully complete the non-clinical analytical studies for three biosimilars with the highest market potential.
- Perform the phase-I clinical validation of the first biosimilar.
This will help Bio-Sourcing close a licensing deal for the sales of the biosimilars to a pharma or biogeneric-producing company by 2027.
Business Model
Bio-Sourcing will remain the exclusive producer and act as a supplier of API to its customers, who will sell fully formulated biosimilars. Bio-Sourcing is expected to receive upfront payments and milestones (€40M in total per biosimilar) and generate longer-term revenue through sales of API and royalty payments on net sales (5%).
Funding Requirements
Bio-Sourcing seeks EICA blended finance (€2.5M grant and €10M equity), which will enable Bio-Sourcing to reach its value inflection point of successfully completing the important Phase I study for the first biosimilar from the BioMilk platform for human health application.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.475.890 |
| Totale projectbegroting | € 2.475.890 |
Tijdlijn
| Startdatum | 1-10-2024 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- BIO SOURCINGpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Scalable and Eco-friendly BioproductionCore Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins. | EIC Accelerator | € 1.153.390 | 2023 | Details |
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approachAlkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Biosensor Activated Biomanufacturing Scale-upEnduro aims to revolutionize microbial biomanufacturing with its synthetic biology plugin, Enduro Sense, to enable scalable processes and attract investment for commercial deployment. | EIC Accelerator | € 1.815.295 | 2023 | Details |
Harnessing the immense potential of precision fermentation to produce animal fats for the next generation of meat and dairy alternativesMelt&Marble develops scalable, precision-fermentation technology to produce customizable, animal-like fats for plant-based foods, enhancing functionality and flavor while reducing environmental impact. | EIC Accelerator | € 2.485.840 | 2025 | Details |
Scalable and Eco-friendly Bioproduction
Core Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins.
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach
Alkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028.
Biosensor Activated Biomanufacturing Scale-up
Enduro aims to revolutionize microbial biomanufacturing with its synthetic biology plugin, Enduro Sense, to enable scalable processes and attract investment for commercial deployment.
Harnessing the immense potential of precision fermentation to produce animal fats for the next generation of meat and dairy alternatives
Melt&Marble develops scalable, precision-fermentation technology to produce customizable, animal-like fats for plant-based foods, enhancing functionality and flavor while reducing environmental impact.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Hydrogen oxidizing bacteria engineered to valorize CO2 for whey protein productionProject HYDROCOW aims to develop a sustainable, net-zero carbon dairy protein production platform using engineered bacteria to convert CO2 into food-grade protein, reducing environmental impacts. | EIC Pathfinder | € 3.963.836 | 2023 | Details |
De MobiGoatHet project ontwikkelt een mobiele geitenmelkinstallatie met hoge capaciteit en lagere kosten om veehouders te ondersteunen bij de overstap van koeien- naar geitenmelk. | Mkb-innovati... | € 69.160 | 2016 | Details |
Productie van nieuwe vleesvervangers op basis van microbieel eiwitDalco Food en BioscienZ ontwikkelen een technologie voor de grootschalige productie van microbiële eiwitten uit groente- en fruitreststromen, gericht op efficiënte vleesvervangers en voedselveiligheid. | Mkb-innovati... | € 113.663 | 2018 | Details |
Biopharmaceuticals purification by continuous membrane-assisted crystallization achieving lower cost and intensified processesThe BIOPURE project aims to revolutionize monoclonal antibody purification using innovative membrane technology to enhance efficiency, reduce costs, and improve access to biomedicines. | EIC Transition | € 2.069.150 | 2023 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Hydrogen oxidizing bacteria engineered to valorize CO2 for whey protein production
Project HYDROCOW aims to develop a sustainable, net-zero carbon dairy protein production platform using engineered bacteria to convert CO2 into food-grade protein, reducing environmental impacts.
De MobiGoat
Het project ontwikkelt een mobiele geitenmelkinstallatie met hoge capaciteit en lagere kosten om veehouders te ondersteunen bij de overstap van koeien- naar geitenmelk.
Productie van nieuwe vleesvervangers op basis van microbieel eiwit
Dalco Food en BioscienZ ontwikkelen een technologie voor de grootschalige productie van microbiële eiwitten uit groente- en fruitreststromen, gericht op efficiënte vleesvervangers en voedselveiligheid.
Biopharmaceuticals purification by continuous membrane-assisted crystallization achieving lower cost and intensified processes
The BIOPURE project aims to revolutionize monoclonal antibody purification using innovative membrane technology to enhance efficiency, reduce costs, and improve access to biomedicines.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.